with CT in the context of SPECT/CT and PET/CT [PR IV.A.5.a).(1).(a).(ii).(l)] therapeutic administration of radioiodine for both malignant and benign thyroid disease, including: patient selection; evaluating risks and benefits; determining the administered activity; patient identity verification; obtaining informed consent; documenting pregnancy status; using administrative controls to prevent a medical event; complying with federal and state regulations regarding medical use of radiopharmaceuticals; counseling patients and their families about radiation safety issues; and scheduling and performing post-therapy follow-up [PR IV.A.5.a).(1).(a).(ii).(m)] therapeutic administration of other unsealed radiopharmaceuticals for malignant and benign diseases, including: patient selection; evaluating risks and benefits; determining the administered activity; patient identity verification; obtaining informed consent; documenting pregnancy status; using administrative controls to prevent a medical event; complying with federal and state regulations regarding the medical use of radiopharmaceuticals; counseling patients and their families about radiation safety issues; and scheduling and performing post-therapy follow-up [PR IV.A.5.a).(1).(a).(ii).(n)]
with CT in the context of SPECT/CT and PET/CT [PR IV.A.5.a).(1).(a).(ii).(l)] therapeutic administration of radioiodine for both malignant and benign thyroid disease, including: patient selection; evaluating risks and benefits; determining the administered activity; patient identity verification; obtaining informed consent; documenting pregnancy status; using administrative controls to prevent a medical event; complying with federal and state regulations regarding medical use of radiopharmaceuticals; counseling patients and their families about radiation safety issues; and scheduling and performing post-therapy follow-up [PR IV.A.5.a).(1).(a).(ii).(m)] therapeutic administration of other unsealed radiopharmaceuticals for malignant and benign diseases, including: patient selection; evaluating risks and benefits; determining the administered activity; patient identity verification; obtaining informed consent; documenting pregnancy status; using administrative controls to prevent a medical event; complying with federal and state regulations regarding the medical use of radiopharmaceuticals; counseling patients and their families about radiation safety issues; and scheduling and performing post-therapy follow-up [PR IV.A.5.a).(1).(a).(ii).(n)]